News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Immunic released favorable updated results for the Phase II EMPhASIS clinical trial investigating the safety and efficacy of vidofludimus calcium to treat relapsing-remitting multiple sclerosis.
Third Rock Ventures Fund VI, providing the company with $1.1 billion to invest in new life science companies. This brings Third Rock to a total of $3.8 billion across its venture funds.
Boehringer Ingelheim signed an option to acquire Trutino Biosciences for an undisclosed amount if certain milestones under its existing partnership are achieved.
The World Health Organization is giving the monkeypox virus a new name soon in an attempt to quell the stigma and discrimination that might go with it.
Biopharma has been stepping up research and drug development against COVID-19 -though results haven’t always been encouraging. Here are the latest stories from this space:
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
Black/African American hematological cancer patients tend to have the worst outcomes. This is partly driven by a lack of access to allogeneic hematopoietic stem cell transplant and available donors.
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
Dren Bio announced the completion a of $65M Series B financing round. New investors include Pfizer, ArrowMark Partners and Revelation Partners.
Despite geopolitical tensions, the pharmaceutical industry sees China as a land of opportunity and some largely surmountable challenges.